Home
APVO
APVO News

Latest Aptevo Therapeutics Inc. (APVO) News on October 8, 2025

ACCESS Newswire

a month ago

Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo announces addition of preclinical candidate APVO455 to portfolio

TipRanks

4 months ago

Aptevo announces addition of preclinical candidate APVO455 to portfolio

MT Newswires

4 months ago

Aptevo Closes $8 Million Offering of Stock, Warrants; Shares Fall

MT Newswires

4 months ago

Top Midday Gainers

MT Newswires

4 months ago

Aptevo Therapeutics Launches $8 Million Offering

ACCESS Newswire

4 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

4 months ago

Aptevo Says Its Mipletamig Therapy Achieves 85% Remission Rate in Leukemia Patients; Shares Soar Pre-Bell

ACCESS Newswire

4 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

ACCESS Newswire

4 months ago

Aptevo Participating in the BIO International Convention

ACCESS Newswire

5 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

ACCESS Newswire

5 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

ACCESS Newswire

5 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

ACCESS Newswire

6 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

6 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

6 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

6 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

Benzinga

7 months ago

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

ACCESS Newswire

7 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire

7 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

ACCESS Newswire

7 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

8 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESS Newswire

8 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

ACCESS Newswire

9 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

ACCESSWIRE

10 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

ACCESSWIRE

10 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

ACCESSWIRE

10 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

ACCESSWIRE

10 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

ACCESSWIRE

10 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

ACCESSWIRE

a year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

ACCESSWIRE

a year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

ACCESSWIRE

a year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

ACCESSWIRE

a year ago

Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

ACCESSWIRE

a year ago

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

ACCESSWIRE

a year ago

Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

ACCESSWIRE

a year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Participating in the BIO International Convention

ACCESSWIRE

a year ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

ACCESSWIRE

a year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

ACCESSWIRE

a year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

ACCESSWIRE

a year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

ACCESSWIRE

a year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

ACCESSWIRE

2 years ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

ACCESSWIRE

2 years ago

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

ACCESSWIRE

2 years ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

ACCESSWIRE

2 years ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 02/01/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/31/2024

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share

PR Newswire

2 years ago

Greenwave Technology Solutions' Scrap App Continues Capturing Market Share

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.

GlobeNewswire

2 years ago

180 Degree Capital Corp. Nominates Matthew F. McLaughlin for Election to the Board of comScore, Inc.

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023

GlobeNewswire

2 years ago

FAT Brands Foundation Awards Over $250,000 to Local Non-Profits in 2023

Visionary Education Group Established a MOU with Algoma University

PR Newswire

2 years ago

Visionary Education Group Established a MOU with Algoma University

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius

GlobeNewswire

2 years ago

Toro Corp. Announces the Completion of the Sale of the M/T Wonder Sirius

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

Simply Wall St.

2 years ago

Keen Vision Acquisition Corporation (NASDAQ:KVAC) most popular amongst retail investors who own 45% of the shares, institutions hold 32%

Thomson Reuters StreetEvents

2 years ago

Q4 2023 RF Industries Ltd Earnings Call

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results

ACCESSWIRE

2 years ago

RF Industries Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Urgently Secures Engagement with Global Top 5 Automotive OEM

GlobeNewswire

2 years ago

Urgently Secures Engagement with Global Top 5 Automotive OEM

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

PR Newswire

2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem

GlobeNewswire

2 years ago

Northann Corp. Receives Approval from U.S. Patent and Trademark Office for Core Technology in Benchwick 3D Printing Ecosystem

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million

GlobeNewswire

2 years ago

Toro Corp. Announces the Sale of the M/T Wonder Sirius for $33.8 Million with an Expected Net Gain of $20.9 Million

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program

GlobeNewswire

2 years ago

LiveOne (Nasdaq: LVO) Provides Update for Its $10M Stock Repurchase Program

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%

Simply Wall St.

2 years ago

DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) largest shareholders are individual investors with 52% ownership, insiders own 37%

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

GlobeNewswire

2 years ago

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

Exec Edge

2 years ago

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

$Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia$

GlobeNewswire

2 years ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Precipio Announces Christina Valauri joins the Board of Directors

GlobeNewswire

2 years ago

Precipio Announces Christina Valauri joins the Board of Directors

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

GlobeNewswire

2 years ago

Trust Stamp has partnered with Scurid to deliver highly secure, AI-powered in-field authentication for seamless human-machine interaction

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)

Simply Wall St.

2 years ago

Zhongchao First Half 2023 Earnings: US$0.18 loss per share (vs US$0.004 profit in 1H 2022)

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule

Business Wire

2 years ago

Cenntro Regains Compliance with Nasdaq Minimum Bid Price Rule

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

GuruFocus.com

2 years ago

Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

GlobeNewswire

2 years ago

PodcastOne (NASDAQ: PODC) Acquires Exclusive Rights to Hit Podcast Was I In A Cult? From Hosts Liz Iacuzzi and Tyler Measom

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

GlobeNewswire

2 years ago

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM

PR Newswire

2 years ago

PRINCIPAL REAL ESTATE INCOME FUND CONTINUES SHARE REPURCHASE PROGRAM

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering

GlobeNewswire

2 years ago

Linkage Global Inc Announces Pricing of $6,000,000 Initial Public Offering

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company

GlobeNewswire

2 years ago

NCS Multistage Holdings, Inc. Settles Outstanding Commercial Litigation with No Cash Payment By Company

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

GlobeNewswire

2 years ago

Presto’s Voice™ AI Solution Projected to Capitalize on Strong Momentum as Company Releases 2024 Projected Annualized Run Rate

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?

Zacks

2 years ago

HomeTrust Bancshares (HTBI) Soars 5.4%: Is Further Upside Left in the Stock?

PR Newswire

2 years ago

Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university

PR Newswire

2 years ago

MicroAlgo Inc. announced plans to establish a practice base to train graduate students for the university

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Zacks

2 years ago

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Senstar Technologies Reports Third Quarter 2023 Financial Results

PR Newswire

2 years ago

Senstar Technologies Reports Third Quarter 2023 Financial Results

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment

GuruFocus.com

2 years ago

Duluth Holdings Inc (DLTH) Reports Q3 2023 Financial Results Amidst Challenging Retail Environment

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years

Simply Wall St.

2 years ago

Investors in HomeTrust Bancshares (NASDAQ:HTBI) have seen returns of 27% over the past three years

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Business Wire

2 years ago

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire

2 years ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS

PR Newswire

2 years ago

GOLD ROYALTY REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS - CONTINUED GROWTH DRIVEN BY RECENT ACQUISITIONS

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Business Wire

2 years ago

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

ACCESSWIRE

2 years ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

GlobeNewswire

2 years ago

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

Zacks

2 years ago

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

LightPath Technologies, Inc. (NASDAQ:LPTH) Q1 2024 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

2 years ago

Q1 2024 LightPath Technologies Inc Earnings Call

Share on Social Networks: